Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

Core Viewpoint - Dianthus Therapeutics, Inc. has initiated an underwritten public offering of $150 million in common stock or pre-funded warrants, with an additional option for underwriters to purchase up to $22.5 million more [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - The net proceeds from the offering will be used for advancing preclinical and clinical development activities, working capital, and general corporate purposes [2]. - Jefferies, TD Cowen, Evercore ISI, and Stifel are acting as joint book-running managers for the offering [2]. Group 2: Regulatory Information - A shelf registration statement for these securities was filed with the SEC and became effective on October 9, 2024 [3]. - The offering will be conducted only through a written prospectus, including a prospectus supplement [3]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team in biotech and pharma [5].